Related Experiment Video
Updated: May 31, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
El Mehdi Tazi1, Ismail Essadi, Mohamed Fadl Tazi
1Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco. moulay.elmehdi@yahoo.fr
Abstract:
Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.
Insights
Collecting duct carcinoma (CDC) is a rare kidney cancer. A patient with metastatic CDC showed a positive response to sunitinib, a tyrosine kinase inhibitor, in lung and bone metastases.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Collecting duct carcinoma (CDC) is an uncommon and aggressive kidney cancer originating from distal tubules.
- CDC typically exhibits a poor response to conventional systemic therapies, posing significant treatment challenges.
Observation:
- This report details a case of metastatic CDC with significant tumor burden in the lungs and skeleton.
- The patient received treatment with sunitinib, a multi-targeted tyrosine kinase inhibitor.
Findings:
- The metastatic collecting duct carcinoma demonstrated a favorable partial response to sunitinib therapy.
- Both lung and skeletal metastases showed shrinkage, indicating therapeutic activity of sunitinib against CDC.
Implications:
- This case suggests sunitinib may be a potential therapeutic option for metastatic collecting duct carcinoma.
- Further prospective studies are warranted to evaluate the efficacy of multi-targeted tyrosine kinase inhibitors, like sunitinib, in managing metastatic CDC.
